OAKLAND, Calif.--(BUSINESS WIRE)--Omicia, Inc. today announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America® Holdings (LabCorp®) for its clinical trials sequencing services. LabCorp’s broad menu of testing services, combined with Omicia’s flexible, powerful, and easy-to-use genome analysis platform, will allow the companies to provide a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials. Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data, and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers can also store, analyze, and manage their clinical trial data within a highly secure environment.
Help employers find you! Check out all the jobs and post your resume.
